Research Roundup: Distance From A Transplant Center; Medicaid Prenatal …Kaiser Health NewsCentralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and…
Roche nabs European approval for time-saving formulation of Rituxan – FiercePharma
Drug Discovery & Development |
Roche nabs European approval for time-saving formulation of Rituxan
FiercePharma Swiss pharma giant Roche ($RHHBY) is pursuing that game plan for some of its hit biotech drugs–and today it scored a victory when European regulators approved a subcutaneous version of its cancer drug Rituxan (rituximab), known as MabThera overseas. Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News EC approves Roche’s SC formulation of MabThera for common forms of non …News-Medical.net NASDAQ –Wall Street Journal all 12 news articles » |
Ambareesh will be back soon: Arjun Sarja – Times of India
Times of India |
Ambareesh will be back soon: Arjun Sarja
Times of India Rebel Star Ambareesh, who was flown to Singapore for expert medical attention following a lung infection, is well on the path to recovery. In fact, the actor is no longer in hospital and is currently recuperating at a friend’s home in Malaysia. Action … |
EC approves Roche's SC formulation of MabThera for common forms of non … – News-Medical.net
Drug Discovery & Development |
EC approves Roche’s SC formulation of MabThera for common forms of non …
News-Medical.net Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …NASDAQ SYS-CON Media (press release) all 15 news articles » |
Patient Enrollment Completed in Multicenter European REMEDEE Registry of … – SYS-CON Media (press release)
Patient Enrollment Completed in Multicenter European REMEDEE Registry of …SYS-CON Media (press release)The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through …
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – infosalus.com
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
infosalus.com La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – Te Interesa
Redacción Médica |
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
Te Interesa La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … Europa da luz verde a MabThera, de Roche, por la vía subcutáneaRedacción Médica |
Treat sexual problems in lung cancer patients on priority say Experts – Daily News & Analysis
|
Treat sexual problems in lung cancer patients on priority say Experts
Daily News & Analysis Raising an issue that has been ignored for long in the case of lung cancer patients, experts have urged physicians to pay more attention on how such patients suffer difficulties with sexual expression and intimacy. “It is time that doctors and … |
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – TeleCinco.es
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
TeleCinco.es La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |
Patient Enrollment Completed in Multicenter European REMEDEE Registry of … – PR Newswire (press release)
Patient Enrollment Completed in Multicenter European REMEDEE Registry of …PR Newswire (press release)… all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent …